Related references
Note: Only part of the references are listed.Brentuximab vedotin-associated diabetic ketoacidosis: a case report
Damla Koksalan et al.
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES (2023)
Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML
Ekaterina Gurevich et al.
CANCERS (2022)
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
S. Horwitz et al.
ANNALS OF ONCOLOGY (2022)
Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
Sarah Farag et al.
BONE MARROW TRANSPLANTATION (2022)
New Onset Persistent Hyperglycemia with Initiation of Brentuximab Treatment
Joseph B. Quintas et al.
BLOOD (2021)
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
Logan Hahn et al.
SCIENTIFIC REPORTS (2021)
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach et al.
Lancet Haematology (2020)
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
Timothy J. Voorhees et al.
CANCERS (2020)
Adverse reactions related to brentuximab vedotin use: A real-life retrospective study
Beatrice Clarivet et al.
THERAPIE (2019)
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
R. Garcia-Sanz et al.
ANNALS OF ONCOLOGY (2019)
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
Alba M. Redondo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study
Anton Hagenbeek et al.
HAEMATOLOGICA (2019)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience
Khalil Saleh et al.
LEUKEMIA & LYMPHOMA (2018)
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity
Thomas Noesslinger et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial
Owen A. O'Connor et al.
LANCET ONCOLOGY (2018)
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients
Stefanie Gilli et al.
ANNALS OF HEMATOLOGY (2017)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2016)
Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
Ramon Garcia-Sanz et al.
BLOOD (2016)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma
Giuseppe Visani et al.
BLOOD (2014)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
Francesco d'Amore et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
Giuseppe Visani et al.
BLOOD (2011)
Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series
N. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma:: a prospective study from The Gel-Tamo Study Group
Jose Rodriguez et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease
CH Moskowitz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
T Kewalramani et al.
BONE MARROW TRANSPLANTATION (2003)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
Share Paper
